Document Type


Publication Date



This article has been peer reviewed. It is the authors' final version prior to publication in Current Urology Reports. Volume 11, Issue 3, May 2010, Pages 139-146. The published version is available at DOI: 10.1007/s11934-010-0103-y. Copyright © Springer


Many options exist for the treatment of localized prostate cancer. In the decision to choose a therapeutic option for localized disease, many variables need to be considered such as tumor characteristics, clinical stage, the patient's overall health and life expectancy, and preferences of both the physician and patient. Another important consideration is the health-related quality of life (HRQOL) implications of a given treatment option. The importance of HRQOL relative to the potential side effects of prostate cancer treatments has grown over the past few years. Although our collective awareness has increased, objective data on HRQOL for prostate cancer treatment are lacking due to a paucity of prospective clinical trial data. This review defines the concept of HRQOL, discusses what is currently known about the impact of various treatments on HRQOL, and summarizes the recent literature in this area relating to the management of localized prostate cancer.

PubMed ID


Included in

Urology Commons